Sorafenib in clinical practice: Evidence-based use or abuse?

Hepatology

Volumn 55, Issue 4, 2012, Pages 1305-

  Basso, Michele ^a   Basso, Maria ^a   Barone, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DISEASE COURSE; DRUG APPROVAL; EVIDENCE BASED PRACTICE; LETTER; LIVER CELL CARCINOMA; LIVER FUNCTION; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TIME TO PROGRESSION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; PYRIDINES;

EID: 84859151774     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25541     Document Type: Letter

References (2)

1. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, et al.; for SOFIA (Sorafenib Italian Assessment) Study Group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. HEPATOLOGY 2011; 54: 2055-2063.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; for SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.